Exploratory analyses: community sample (17 items) | Confirmatory analysis: clinical trials, one-factor solution (10 items) |
---|
| One-factor solution (n = 141) | Two-factor solution (n = 141) | | BTH yoga study (n = 55) | MAP study (n = 41) | POYSE study (n = 85) |
Total % variance explained | 0.62 | 0.71 | Total % variance explained | 0.61 | 0.65 | 0.74 |
|
Chi-square | 926.7 | 527.8 | SRMSR | 0.07 | 0.05 | 0.05 |
|
Chi-square df | 119 | 103 | ML chi-square | 124.9 | 57.0 | 141.2 |
|
p-Value | <0.001 | <0.001 | Chi-square df | 35 | 35 | 35 |
|
RMSEA (90% CI) | 0.23 (0.21–0.23) | 0.18 (0.16–0.19) | ML chi-square p-value | <0.001 | 0.01 | <0.001 |
|
RMSR | 0.10 | 0.05 | ML RMSEA (90% CI) | 0.22 (0.18–0.26) | 0.12 (0.06–0.18) | 0.19 (0.16–0.22) |
|
TLI | 0.65 | 0.79 | ML TLI | 0.75 | 0.92 | 0.86 |
|
BIC | 337.8 | 18.1 | ML CFI | 0.81 | 0.94 | 0.89 |
| | | Robust chi-square | 54.36 | 49.90 | 80.18 |
| | | Robust chi-square p-value | 0.02 | 0.049 | <0.001 |
| | | Robust RMSEA (90% CI) | 0.10 (0.06–0.13) | 0.10 (0.02–0.16) | 0.12 (0.10–0.15) |
| | | Robust TLI | 0.93 | 0.87 | 0.92 |
| | | Robust CFI | 0.94 | 0.90 | 0.94 |
BIC, Bayesian information criterion; CFI, comparative fit index; CI, confidence interval;
df, degrees of freedom; ML, maximum likelihood; RMSEA, root mean square error of approximation; SRMSR, standardized root mean square residual; TLI, Tucker–Lewis index.